SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cox J,Grignon D,Kaplan R,Parsons J,Schellhammer P. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997; 37: 10351041.
  • 2
    Horwitz EM,Uzzo RG,Hanlon AL,Greenberg RE,Hanks GE,Pollack A. Modifying the ASTRO definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3D conformal radiation therapy alone. J Urol. 2003; 169: 21532159.
  • 3
    Vicini F,Kestin L,Martinez A. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 1999; 45: 553561.
  • 4
    Horwitz E,Vicini F,Ziaja E,Dmuchowski C,Stromberg J,Martinez A. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. Int J Radiat Oncol Biol Phys. 1998; 41: 267272.
  • 5
    Sandler HM,Dunn RL,McLaughlin PW,Hayman JA,Sullivan MA,Taylor JM. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2000; 48: 629633.
  • 6
    Kupelian PA,Buchsbaum JC,Patel C, et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys. 2002; 52: 704711.
  • 7
    Kwan W,Pickles T,Duncan G, et al. PSA failure and the risk of death in prostate cancer patients treated with radiotherapy.[see comment]. Int J Radiat Oncol Biol Phys. 2004; 60: 10401046.
  • 8
    Pollack A,Hanlon AL,Movsas B,Hanks GE,Uzzo R,Horwitz EM. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003; 57: 1923.
  • 9
    Williams SG,Duchesne GM,Millar JL,Pratt GR. Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 60: 10821087.
  • 10
    Buyyounouski MK,Hanlon AL,Eisenberg DF, et al. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys. 2005; 63: 14551462.
  • 11
    Rosser CJ,Kuban DA,Levy LB, et al. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol. 2002; 168: 20012005.
  • 12
    Hanlon AL,Pinover WH,Horwitz EM,Hanks GE. Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys. 2001; 50: 845849.
  • 13
    Horwitz EM,Levy LB,Thames HD, et al. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer. 2006; 107: 14961502.
  • 14
    Thames H,Kuban D,Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003; 57: 929943.
  • 15
    Horwitz EM,Thames HD,Kuban DA, et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol. 2005; 173: 797802.
  • 16
    Roach M3rd,Hanks G,Thames HJr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965974.
  • 17
    Corn BW,Hanks GE,Schultheiss TE,Hunt MA,Lee WR,Coia LR. Conformal treatment of prostate cancer with improved targeting: superior prostate-specific antigen response compared to standard treatment. Int J Radiat Oncol Biol Phys. 1995; 32: 325330.
  • 18
    Monti AF,Ostinelli A,Frigerio M, et al. An ICRU 50 radiotherapy treatment chart. Radiother Oncol. 1995; 35: 145150.
  • 19
    Taylor JM,Griffith KA,Sandler HM. Definitions of biochemical failure in prostate cancer following radiation therapy. Int J Radiat Oncol Biol Phys. 2001; 50: 12121219.
  • 20
    Johnstone PA,Williams SR,Riffenburgh RH. The 100-day PSA: usefulness as surrogate end point for biochemical disease-free survival after definitive radiotherapy of prostate cancer. Prostate Cancer Prostatic Dis. 2004; 7: 263267.
  • 21
    Eade TN,Hanlon AL,Horwitz EM,Buyyounouski MK,Hanks GE,Pollack A. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys. 2007; 68: 682689.
  • 22
    Kuban DA,Thames HD,Levy LB, et al. Failure definition-dependent differences in outcome following radiation for localized prostate cancer. can one size fit all? Int J Radiat Oncol Biol Phys. 2003; 57(2 suppl ): S146S147.
  • 23
    Vicini FA,Kestin LL,Martinez AA. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. [see comment]. Cancer. 2000; 88: 23052318.
  • 24
    Kestin LL,Vicini FA,Martinez AA. Practical application of biochemical failure definitions: what to do and when to do it. Int J Radiat Oncol Biol Phys. 2002; 53: 304315.